NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) ("DocGo†or the "Company†), a leading provider of technology-enabled medical transportation and mobile health services, announced today that it has been recognized as one of the 2026 World's Most Ethical Companies® by Ethisphere, a global leader in defining and advancing the standards of ethical business practices. This is DocGo's first time receiving this honor, and the Company is one of only four honorees in the healthcare providers and ser. ...

DocGo Inc. (DCGO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -457.90%. A quarter ago, it was expected that this company would post a loss of $0.09 per share when it actually produced a loss of $0.11, delivering a surprise of -22.22%.Over the last four quarters, the company has not bee ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $74.9 million, down from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related projects [17] - Adjusted EBITDA for Q4 2025 was a loss of $11.3 million compared to a profit of $1.1 million in Q4 2024 [18] - For the full year 2025, total revenue was $322.2 million, down from $616.6 million in 2024, with an adjusted EBITDA loss of $28.6 million compared to a profit of $60 million in 2024 [18][19] Business Line Data and Key Metrics Changes - Medical transportation services revenue increased to $50.2 million in Q4 2025 from $49.1 million in Q4 2024, driven by growth in both large and small U.S. markets [17][18] - Mobile Health revenue for Q4 2025 was $24.8 million, down from $71.8 million in Q4 2024, but non-migrant Mobile Health revenues increased by 47% [18][19] - SteadyMD generated over $8 million in revenue for the first time in Q4 2025, contributing $6.1 million to DocGo's results [7][8] Market Data and Key Metrics Changes - Medical transportation trips increased by 11%, healthcare in-home visits were up 113%, and telehealth and lab orders were up 50% compared to Q4 2024 [10] - The number of assigned lives in the care gap closure program increased by 12% sequentially, from 1.3 million to over 1.45 million [11] Company Strategy and Development Direction - The company is focused on integrating SteadyMD into its mobile health offerings and aims to consolidate provider networks by the end of Q2 2026 [8] - DocGo is exploring strategic alternatives to maximize shareholder value, engaging an investment bank for this process [15][28] - The company plans to reduce cash outlay in 2026 as early markets mature and become self-sustaining, with a goal of achieving profitability in the second half of 2026 [12][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong demand for services and top-line growth, with an updated revenue guidance for 2026 of $290 million to $310 million [6][25] - The adjusted EBITDA loss is expected to improve to a range of $5 million to $10 million for 2026, down from previous guidance of $15 million to $25 million [26] - Management highlighted the importance of reducing SG&A expenses by 10%-15% through efficiency innovations [32] Other Important Information - The company incurred significant non-cash charges due to the write-down of intangible assets and goodwill, totaling $49.5 million and $22.6 million respectively in Q4 2025 [22] - Cash and cash equivalents at year-end were $68.3 million, down from $95.2 million, primarily due to the acquisition of SteadyMD and delays in collecting migrant-related accounts receivable [23][24] Q&A Session Summary Question: Can you provide details on the strategic alternatives process? - The company has engaged an investment bank to maximize shareholder value but cannot share further details at this time [28][29] Question: What are the drivers behind the increased 2026 guidance? - Increased volumes in Medical Transportation and additional upside from SteadyMD are the primary drivers for the revenue outlook increase [30][31] Question: Can you quantify free cash flow pressures in 2026? - The cash balance at year-end was lower than expected due to delays in collecting $20 million in migrant receivables, but the outlook for collectibility remains unchanged [36][39] Question: What is the status of the payer business and pipeline? - The company continues to see momentum in the payer business, with significant increases in visits and lives referred by payers [45][48] Question: How should we think about EBITDA cadence throughout the year? - Most of the adjusted EBITDA loss is expected in the first half of the year, with a turn to profitability in the second half [70][71]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $74.9 million, down from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related projects. Excluding these revenues, there was an 11% year-over-year increase in revenue for Q4 [24] - For the full year 2025, total revenue was $322.2 million compared to $616.6 million in 2024. Adjusted EBITDA for Q4 2025 was a loss of $11.3 million, compared to a gain of $1.1 million in Q4 2024 [27] - The adjusted gross margin for Q4 2025 was 32.5%, down from 33.5% in Q4 2024, with medical transportation segment margins improving to 32.8% from 30.1% [28] Business Line Data and Key Metrics Changes - Medical transportation services revenue increased to $50.2 million in Q4 2025 from $49.1 million in Q4 2024, driven by growth in both large and small U.S. markets [25] - Mobile Health revenue for Q4 2025 was $24.8 million, down from $71.8 million in Q4 2024, but non-migrant Mobile Health revenues increased by 47% [26] - SteadyMD generated over $8 million in revenue for the first time in Q4 2025, contributing $6.1 million to DocGo's results [10] Market Data and Key Metrics Changes - The number of patient interactions for SteadyMD exceeded 4 million in 2025, up from approximately 2.5 million in 2024, indicating strong growth in telehealth services [11] - The care gap closure program saw a 12% sequential gain in assigned lives, increasing from 1.3 million to over 1.45 million [16] Company Strategy and Development Direction - The company is focused on integrating SteadyMD into its mobile health offerings and aims to consolidate provider networks by the end of Q2 2026 [11] - DocGo is exploring strategic alternatives to maximize shareholder value, engaging an investment bank for this process [22] - The company plans to reduce cash outlay as early markets mature and become self-sustaining, targeting profitability in the second half of 2026 [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about revenue growth driven by new customer expansions and improved hiring rates, raising 2026 revenue guidance to $290 million-$310 million [9] - The adjusted EBITDA loss is expected to improve to $5 million-$10 million in 2026, down from previous projections of $15 million-$25 million [39] - Management highlighted the importance of technology and automation in driving efficiency and reducing costs while maintaining high service levels [92] Other Important Information - The company incurred significant non-cash charges due to write-downs of intangible assets and goodwill, totaling $49.5 million and $22.6 million respectively in Q4 [34] - Cash and cash equivalents at year-end were $68.3 million, down from $95.2 million, primarily due to the acquisition of SteadyMD and delays in collecting migrant-related receivables [35][36] Q&A Session Summary Question: Can you provide details on the strategic alternatives process? - Management confirmed engagement with an investment bank to maximize shareholder value but could not disclose further details at this time [43] Question: What are the components driving the increased 2026 guidance? - The increase in guidance is primarily driven by improved volumes in the Medical Transportation segment and additional upside from SteadyMD [44][46] Question: Can you quantify free cash flow pressures in 2026? - Management indicated that cash balance was lower than expected due to delays in collecting $20 million in migrant receivables, but they expect to collect all of it [54][56] Question: What is the outlook for the payer business and potential new contracts? - Management noted ongoing momentum in the payer business and the potential for additional contracts, but current guidance is based on existing contracts and staffing [63][66] Question: How should we think about EBITDA cadence throughout 2026? - Most of the adjusted EBITDA loss is expected in the first half of the year, with a turnaround to profitability anticipated in the second half [90]

Financial Data and Key Metrics Changes - The company reported $74.9 million in revenue for Q4 2025, down from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related projects [15] - For the full year 2025, total revenue was $322.2 million compared to $616.6 million in 2024 [15] - Adjusted EBITDA loss for Q4 2025 was $11.3 million, compared to a profit of $1.1 million in Q4 2024 [16] - The adjusted gross margin for Q4 2025 was 32.5%, down from 33.5% in Q4 2024 [17] Business Line Data and Key Metrics Changes - Medical transportation services revenue increased to $50.2 million in Q4 2025 from $49.1 million in Q4 2024 [15] - Mobile Health revenue for Q4 2025 was $24.8 million, down from $71.8 million in Q4 2024, but non-migrant Mobile Health revenues increased by 47% [16] - SteadyMD generated $6.1 million in revenue for DocGo in Q4 2025, with full-year gross margins improving from approximately 30% to 37% [6][17] Market Data and Key Metrics Changes - The company saw strong growth in markets like New York, Texas, and Tennessee, contributing to revenue increases in medical transportation [16] - The number of assigned lives in the care gap closure program increased by 12% sequentially, from 1.3 million to over 1.45 million [10] Company Strategy and Development Direction - The company is focused on integrating SteadyMD into its mobile health offerings and aims to consolidate provider networks by the end of Q2 2026 [7] - The company plans to reduce cash outlay in 2026 as early markets mature and become self-sustaining, with a goal of achieving profitability in the second half of 2026 [11] - An efficiency innovation portfolio has been launched, expected to deliver $5-$6 million in savings in 2026 and $20-$24 million in 2027 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong demand for services and top-line growth across volume metrics, despite challenges in achieving profitability [14] - The company anticipates a full-year adjusted EBITDA loss in the range of $5 million to $10 million for 2026, an improvement from previous guidance [24] - Management highlighted the importance of technology and automation in driving efficiency and reducing costs while maintaining high service levels [70] Other Important Information - The company has initiated a process to explore strategic alternatives aimed at maximizing shareholder value [13] - Cash and cash equivalents at year-end were $68.3 million, down from $95.2 million, primarily due to the acquisition of SteadyMD and delays in collecting migrant-related accounts receivable [21][22] Q&A Session Summary Question: Can you provide details on the strategic alternatives process? - The company has engaged an investment bank to run a formal process aimed at maximizing shareholder value, but cannot share further details at this time [26] Question: What are the components driving the increased 2026 guidance? - The increase in revenue guidance is primarily driven by improved volumes in the Medical Transportation segment and additional upside from SteadyMD [28] Question: Can you quantify the free cash flow pressures in 2026? - The company expects cash balance to be lower due to working capital requirements and ongoing operating losses, but anticipates collecting outstanding receivables [33][36] Question: What is the outlook for the payer business and pipeline? - The company continues to see momentum in the payer business, with an increase in covered lives and ongoing discussions with potential new payers [41][46] Question: How should we think about EBITDA cadence throughout the year? - Most of the adjusted EBITDA loss is expected in the first half of the year, with a transition to profitability in the second half as efficiency measures take effect [68]

DocGo Announces Fourth Quarter and Full Year 2025 Results Mar 16, 2026 4:05 PM Eastern Daylight Time DocGo Announces Fourth Quarter and Full Year 2025 Results Share Company Raises 2026 Revenue and Adjusted EBITDA Guidance due to Customer Expansions, Improved EMS Hiring Rates and Efficiency Initiatives Company Has Initiated a Formal Process to Explore Strategic Alternatives to Maximize Shareholder Value Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK--(BUSINESS WIRE)--Do ...

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of DocGo Inc. (NASDAQ: DCGO) towards shareholders [1] Group 1: Investigation Details - The investigation focuses on whether the actions of DocGo's insiders have harmed shareholder interests [1] - Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation [1] Group 2: Shareholder Rights and Options - Long-term shareholders of DocGo may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [1] - Participation of shareholders is emphasized as a means to improve company policies and enhance shareholder value [1] Group 3: Legal Representation - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct [1] - The firm has successfully implemented corporate reforms and recovered millions for defrauded investors [1]

Core Viewpoint - DocGo is positioning itself as a leader in mobile healthcare and medical transportation, targeting a revenue of $280 million to $300 million by 2026, excluding COVID-related and asylum/migrant work, focusing on its core medical transportation and mobile healthcare services [1][6]. Business Operations - In 2025, DocGo conducted over 700,000 patient transports, completed 150,000 in-home patient visits, remotely monitored approximately 55,000 patients, and performed over 1 million telehealth visits [2]. - The company operates nearly 1,000 vehicles and employs more than 3,000 clinical staff, having served over 10 million patients since its inception [2]. Strategic Positioning - DocGo aims to deliver "proactive healthcare at any address," improving access and reducing unnecessary emergency department utilization, addressing healthcare system capacity constraints and rising chronic diseases [3]. - The company is expanding its mobile health footprint to close care gaps and pursue value-based care, bolstered by the acquisition of SteadyMD, which contributed over $25 million in revenue and more than 1 million telehealth visits [4]. Revenue and Financial Guidance - Medical transportation is projected to generate over $200 million in revenue this year, supported by significant operational scale [5]. - DocGo guided for an adjusted EBITDA loss of $15 million to $25 million, expecting to exit the year at a break-even run rate, with approximately $95 million in cash and no outstanding debt as of Q3 [6][7]. Customer Relationships - The company collaborates with large health systems and major insurance payers, relying on referrals rather than direct-to-consumer marketing [8]. - DocGo has established relationships with hospital systems such as Northwell and Mount Sinai, and payers including Molina and Anthem, achieving a patient Net Promoter Score above 92 [9]. Mobile Health Services - DocGo performs over 40 different types of care gap services in-home, including diabetic checks and wellness visits, aiming to bring the capabilities of a doctor's office into patients' homes [12]. - The operational model pairs clinicians with remote advanced providers to maximize efficiency and address social determinants of health [13]. Technology Integration - The company has developed an "Uber-like" logistics platform integrated with Epic, enhancing transparency and coordination in medical transportation [15][16]. - DocGo's technology is designed to optimize field efficiency by matching clinicians, vehicles, and patient needs, providing precise arrival windows [16]. Long-term Opportunities - The company believes it is well-positioned for value-based arrangements due to its home-based operations and remote patient monitoring capabilities [18]. - Bienstock highlighted the importance of scaling medical transportation and the potential benefits from CMS programs rewarding better health outcomes [18].

Summary of DocGo Conference Call Company Overview - **Company**: DocGo - **Industry**: Mobile healthcare and medical transport services - **Key Services**: Technology-enabled mobile healthcare, medical transportation, telehealth services Core Points and Arguments - **Business Model**: DocGo delivers healthcare directly to patients' homes using a fleet of medical transportation vehicles and mobile healthcare units, aiming to enhance patient convenience and reduce hospital visits [2][3] - **Scale of Operations**: In 2025, DocGo conducted over 700,000 patient transports, visited patients at home 150,000 times, and performed over 1 million telehealth visits [3][4] - **Patient Satisfaction**: The company boasts a Net Promoter Score of over 92, indicating high patient satisfaction [4] - **Revenue Guidance**: For 2026, DocGo projects revenue between $280 million and $300 million, excluding COVID-related revenues [6][8] - **Financial Health**: As of Q3 of the previous year, DocGo reported $71 million in quarterly revenue, with $50 million from medical transportation and $20 million from mobile health services. The company has no outstanding debt and $95 million in cash [7][8] - **Growth Trajectory**: The company has seen consistent growth in its medical transportation and mobile health business, driven by partnerships with large hospital systems and insurance companies [5][6] Industry Context - **Healthcare Challenges**: Approximately 160 million Americans have at least one chronic condition, and less than half have a consistent primary care provider. The healthcare infrastructure is inadequate to meet the growing demand [9][10] - **Value-Based Care**: The shift towards value-based care is emphasized, where healthcare providers are incentivized to keep patients healthy rather than just treating them when they are sick [15][35] Technology and Competitive Advantage - **Tech Stack**: DocGo's technology platform is designed for operational efficiency, allowing for real-time patient monitoring and care delivery. The platform integrates with hospital systems like Epic, providing transparency and optimizing patient flow [39][40] - **Unique Value Proposition**: Unlike competitors, DocGo combines multiple services (mobile healthcare, telehealth, medical transportation) into a cohesive offering, addressing various patient needs [27][28] Future Opportunities - **Expansion Potential**: DocGo plans to scale its services across states, leveraging existing partnerships with national insurance providers and hospital systems for cross-selling opportunities [30][42] - **Value-Based Care Leadership**: The company aims to position itself as a leader in value-based care by leveraging its home healthcare model and deep patient insights [43][44] Additional Insights - **Patient Engagement**: DocGo's approach includes addressing social determinants of health by observing patients' living conditions during home visits, which can inform better care strategies [14][16] - **Market Positioning**: The company believes it is uniquely positioned to capitalize on the growing demand for home-based healthcare solutions, as traditional healthcare delivery models struggle to meet patient needs [29][31] This summary encapsulates the key points discussed during the DocGo conference call, highlighting the company's operations, market context, technological advantages, and future growth strategies.

Core Viewpoint - DocGo Inc. is set to release its financial results for Q4 and the full year ending December 31, 2025, on March 16, 2025, after market close [1] Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 5:00 p.m. ET on the same day [1]